Research programme: p38/MEK-targeting molecules - Signal Research Division

Drug Profile

Research programme: p38/MEK-targeting molecules - Signal Research Division

Alternative Names: p38/MEK-targeting molecules research programme - Signal Research Division

Latest Information Update: 26 Apr 2007

Price : $50

At a glance

  • Originator Signal Research Division
  • Class
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 07 Nov 2003 This programme is still in active development
  • 07 Sep 2000 Signal Pharmaceuticals has been acquired by Celgene
  • 26 Jan 2000 Available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top